Skip to main content
Article
SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
Internal Medicine Journal (2018)
  • P. Nash
  • L. C. Coates
  • A. J. Kivitz
  • P. J. Mease
  • D. D. Gladman
  • J. A. Covarrubias-Cobos
  • D. Fleishaker
  • C. Wang
  • E. Kudlacz
  • S. Menon
  • L. Fallon
  • T. Hendrikx
  • K. S. Kanik
Publication Date
May 1, 2018
Citation Information
P. Nash, L. C. Coates, A. J. Kivitz, P. J. Mease, et al.. "SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY" Internal Medicine Journal Vol. 48 (2018) p. 15 - 15
Available at: http://works.bepress.com/philip-mease/365/